Screening of Lysosomal Storage Disorders Diseases in Minority Groups
Enzymatic and Genotypic Screening of Lysosomal Storage Diseases in Minority Groups
1 other identifier
observational
100,000
1 country
1
Brief Summary
Aim is to undertake a screening study that identifies undiagnosed patients with LSDs and determine the prevalence of these diseases with special focus on underrepresented minority groups.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2016
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 17, 2016
CompletedFirst Submitted
Initial submission to the registry
January 18, 2019
CompletedFirst Posted
Study publicly available on registry
January 22, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2019
CompletedJanuary 22, 2019
January 1, 2019
3.7 years
January 18, 2019
January 18, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Enzyme activity analysis to identify subjects with Lysosomal storage disorders
To identify patients with LSDs using enzymatic activity specific to individual lysosomal storage disorders using left-over blood of blood samples collected as part of standard clinical care.
5 years
Genotypic analysis of subjects with abnormal enzyme activity
Samples from subjects with abnormally low enzyme activity will be used for targeted sequencing analysis to diagnose any pathologic mutations.
5 years
Study Arms (1)
Screen population
The study population will comprise of patients of healthcare institutions in the Washington, D.C. metro area including but not limited to hospitals, clinics, and doctor's offices.
Interventions
Enzyme assay and molecular sequencing on relevant samples conducted from left over blood samples
Eligibility Criteria
The study population will comprise of patients of healthcare institutions in the Washington, D.C. and Richmond, Virginia areas including but not limited to hospitals, clinics, and doctor's offices.
You may qualify if:
- Subject is greater than or equal to 1 day of age and less than or equal to 100 years of age
- Subject is managed by a physician in the Washington, D.C and Richmond, VA metro area
- Subject is getting blood work as part of standard clinical care and there is at least 60 uL blood remained in a tube after all clinical tests were run
You may not qualify if:
- Absolute contraindication for blood drawing
- Subject cannot be traced back by the referring physician upon a positive screening result
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
LDRTC
Fairfax, Virginia, 22030, United States
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Renuka Limgala, PhD
LDRTC
- PRINCIPAL INVESTIGATOR
Margarita M Ivanova, PhD
LDRTC
- PRINCIPAL INVESTIGATOR
Ozlem Goker-Alpan, MD
LDRTC
Study Design
- Study Type
- observational
- Observational Model
- ECOLOGIC OR COMMUNITY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 18, 2019
First Posted
January 22, 2019
Study Start
March 17, 2016
Primary Completion
December 1, 2019
Study Completion
December 1, 2019
Last Updated
January 22, 2019
Record last verified: 2019-01